GlassScriptPhysician profile
Soojung Yoo
NPI 1295406502
$2,088.23
in general payments reported to CMS, 2019-2025
23 companies · $955 in 2025
The $955 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $196 · 2023: $505 · 2024: $432 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $436.76 | 2024-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $237.73 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $197.59 | 2025 | Spravato, Invega Sustenna |
| Glaxosmithkline, LLC. | $184.99 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $159.87 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $132.90 | 2022-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $115.85 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $77.18 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Nestle Healthcare Nutrition INC. | $69.44 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.24 | 2022-2024 | Jardiance |
| Ironwood Pharmaceuticals, INC | $55.57 | 2023-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.86 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $39.91 | 2023 | |
| Ucb, INC. | $37.97 | 2025 | Zilbrysq |
| Vivus LLC | $37.11 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2025 | Cobenfy |
| Abiomed | $29.21 | 2023 | Impella |
| Sumitomo Pharma America, INC. | $26.54 | 2023 | Gemtesa |
| Neurocrine Biosciences, INC. | $24.59 | 2025 | |
| Almatica Pharma LLC | $24.07 | 2025 | Loreev Xr |
| Amgen INC. | $23.52 | 2023 | Prolia |
| Sunovion Pharmaceuticals INC. | $18.96 | 2022 | |
| Pfizer INC. | $14.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soojung Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.